Hook & thesis
RadNet is behaving like two companies in one: an outpatient imaging operator benefiting from a steady post-pandemic volume recovery, and a fast-growing digital health platform (DeepHealth) that is scaling commercial AI offerings after the completion of the Gleamer acquisition. I think the market is under-appreciating the revenue leverage from AI product rollouts and the potential margin lift as DeepHealth transitions from R&D to commercial sales. That combination makes a tactical long trade attractive here, using the stock's current momentum—RSI ~72 and bullish MACD—as an entry signal but keeping a tight stop to manage integration and cash-flow risk.
Why the market should care
RadNet operates a large outpatient imaging franchise and is pushing to become a major vendor of clinical radiology AI through its DeepHealth unit. The business mix matters: imaging centers produce recurring revenue tied to scan volumes and reimbursement, while digital health products offer higher growth and potentially much higher gross margins. Management delivered record Q4 2025 revenue of $547.7 million (+14.8% YoY) and adjusted EBITDA of $87.7 million (+16.9% YoY), then put $270 million toward buying Gleamer to accelerate clinical AI scale. Guidance for 2026 called for imaging center revenue growth of 17-19% and digital health revenue growth of 46-56% - if achieved, that should materially re-rate the digital health multiple embedded in the shares.
Fundamentals in numbers
- Current price: $76.27.
- Market cap: roughly $6.94 billion and enterprise value around $6.64 billion.
- Q4 2025 revenue: $547.7 million (record); adjusted EBITDA: $87.7 million.
- Recent acquisition: Gleamer for $270 million to bolster DeepHealth and expand clinical AI offerings.
- Balance sheet snapshot: cash roughly $720 million; free cash flow negative ~$332 million (trailing figure); debt-to-equity ~1.01; current ratio ~1.17.
- Valuation multiples: price-to-sales ~2.8x; EV/EBITDA ~27.1x; price-to-book ~5.56x.
The combination of substantive revenue growth in imaging and very high expected growth in Digital Health (management guided mid-to-high double digits) implies a two-speed story: stable recurring cash from centers and rapid top-line leverage from AI products. The commercial launch of 'Reporting Pro' and planned international deployments give the digital health line tangible near-term revenue levers beyond internal use cases.
Technical & market context
Technically, the shares show strong momentum: the 9-day EMA (~$70.54) is below price, SMA series are rising, and MACD is signaling bullish momentum. RSI is elevated (~72.6), so the stock is extended in the very short-term; that argues for measured position sizing or using a staggered entry. Short interest has been non-trivial—recent settlement shows ~10.4M shares short and days-to-cover near 17 as of 07/31/2026—so volatility around news events can be amplified.
Valuation framing
At a market cap near $6.9 billion and an EV/EBITDA near 27x, RadNet is trading at a premium to a typical outpatient imaging operator. That premium is justified only if digital health becomes a meaningful and high-margin revenue contributor. Price-to-sales of ~2.8x and EV-to-sales ~3.1x indicate the market is paying for revenue growth expectations, not current profits: EPS remains negative (roughly -$0.18 trailing), and free cash flow was negative in the trailing period. The balance sheet still carries leverage (debt-to-equity ~1.01) but also ample cash (~$720M), which funded the Gleamer deal and provides runway for integrations and commercial expansion.
Put simply, you are paying growth-forward multiples. The bull case requires DeepHealth to convert product launches (Reporting Pro and Gleamer's modules) into recurring contracts with hospitals and imaging networks at meaningful ASPs and retention. If that happens, multiples compressing relative to peers with similar growth and margin profiles becomes plausible; if not, the premium is at risk.
Catalysts (what to watch)
- Commercial rollouts of Reporting Pro in the US and UK and planned deployments in Australia, South Africa, and Europe - each region conversion is a revenue milestone.
- Integration updates and cross-sell wins from the Gleamer acquisition - investor presentations and dedicated calls (company hosted an investor call on 03/05/2026) should reveal pipeline metrics.
- Quarterly results that show progress on digital health revenue growth and margin expansion; management guided 46-56% digital health growth for 2026.
- Large hospital network contracts or multi-site deployments of DeepHealth modules; these are binary re-rating events if signed and announced.
- Macro healthcare volumes and reimbursement trends - imaging centers are still exposed to utilization shifts.
Trade idea - actionable plan
This is a bullish trade with disciplined risk controls. I recommend initiating a position at the current price, using a stop to protect against integration setbacks and a realistic upside target that prices in successful digital health monetization.
| Entry | Primary Target | Stop Loss | Time Horizon | Risk Level |
|---|---|---|---|---|
| $76.27 | $88.00 | $70.00 | Long term (180 trading days) | Medium |
Plan details:
- Entry price: $76.27. Consider scaling in half at entry and adding on a pullback toward the 9-day EMA (~$70.54) if market weakness presents a better price.
- Stop loss: $70.00. A break below $70 would indicate both technical momentum loss and proximity to the 9-day EMA support area — it also drastically reduces reward-to-risk if the story stalls.
- Primary target: $88.00 by long term (180 trading days). This price assumes continued imaging volume recovery, initial commercial traction from Reporting Pro and Gleamer modules, and a multiple expansion tied to higher digital health revenue contribution.
- Intermediate target: $82.00 by mid term (45 trading days). Use this to take partial profits if momentum stalls before the longer-term digital health catalysts materialize.
Why this makes sense
The trade balances momentum and fundamentals. Management has posted sequential revenue growth (record Q4 2025 revenue of $547.7M), made a sizable strategic acquisition ($270M for Gleamer), and launched commercial products (Reporting Pro). If DeepHealth hits the guided 46-56% growth while Imaging grows ~17-19%, the business mix will shift meaningfully toward higher-growth, higher-margin software revenue — a classic re-rating dynamic. The company also has ~ $720M in cash to run and scale the business while integrating Gleamer, which reduces the near-term financing overhang risk.
Risks and counterarguments
- Integration risk: Acquisitions often take longer to deliver synergies than expected. Failure to integrate Gleamer cleanly would delay revenue conversion and could force management to cut near-term targets.
- Cash burn & FCF pressure: Trailing free cash flow was negative ~ $332M. If digital health revenue ramps slower than planned, RadNet could face continued cash outflows, pressuring the multiple and potentially forcing dilution or higher leverage.
- Execution & commercial sales risk: Selling AI into hospitals requires procurement approvals, clinical validation and convincing CFOs of economic ROI. Adoption timelines can be long; missed commercial milestones would undercut the bull case.
- Valuation premium vulnerability: EV/EBITDA ~27x and P/S ~2.8x imply a high bar. If growth disappoints or macro risks compress multiples, the stock could correct sharply.
- Technical and sentiment risks: RSI is elevated and short interest remains material (recent reads ~10M shares with days-to-cover spiking near ~17). That combination can create abrupt moves on news; the stock can be volatile to the upside and downside.
Counterargument to the bull case: One could argue the market is already pricing in a successful DeepHealth monetization given the premium multiples. If digital health growth disappoints or the Gleamer integration drags on, cash burn and negative EPS could lead to a sharp multiple contraction. In that scenario, the stock would likely underperform until profitable and sustained digital health revenue growth is demonstrated.
What would change my mind
I would downgrade the trade if: (a) management provides quarter-over-quarter revenue/ARR cadence that misses digital health growth targets; (b) free cash flow deterioration accelerates materially beyond the current negative ~$332M level without a clear remedial plan; or (c) material regulatory or clinical setbacks slow commercial adoption of core AI modules. Conversely, conviction would rise if RadNet announces multi-site hospital deployments, recurring SaaS-style contract wins, or faster-than-expected margin expansion in DeepHealth.
Conclusion
RadNet sits at an inflection point: a stable imaging business financing an aggressive push into clinical AI. That positioning justifies a measured, catalyst-driven long trade. Entry at $76.27 with a $70 stop and a primary target of $88 balances upside tied to digital health execution against clear near-term risks from integration, cash flow, and valuation. Keep position sizing prudent and watch commercial rollout metrics closely; those will determine whether a premium multiple is sustainable.
Key near-term watch items: Reporting Pro deployments, Gleamer integration milestones, quarterly digital health revenue cadence, and hospital contract announcements.